William Mack & Associates’s Alnylam Pharmaceuticals ALNY Stock Holding History

William Mack & Associates’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.23K	Buy	+5	New	+$1.27K	﹤0.01%	672

Other funds holding ALNY

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

William Mack & Associates's ALNY Position: Q3 2026 in Review

William Mack & Associates opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 5 shares worth $1.23K. The stake represents ﹤0.01% of the portfolio and ranks #672 among its holdings.

591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

William Mack & Associates held 5 shares of Alnylam Pharmaceuticals worth $1.23K as of Q3 2026.
Alnylam Pharmaceuticals was a new William Mack & Associates position in Q3 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #672 holding.
591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.